CN101312967B - 作为5-ht4受体激动剂的氨基甲酸酯化合物 - Google Patents

作为5-ht4受体激动剂的氨基甲酸酯化合物 Download PDF

Info

Publication number
CN101312967B
CN101312967B CN2006800433139A CN200680043313A CN101312967B CN 101312967 B CN101312967 B CN 101312967B CN 2006800433139 A CN2006800433139 A CN 2006800433139A CN 200680043313 A CN200680043313 A CN 200680043313A CN 101312967 B CN101312967 B CN 101312967B
Authority
CN
China
Prior art keywords
compound
propyl
formula
carbonyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800433139A
Other languages
English (en)
Chinese (zh)
Other versions
CN101312967A (zh
Inventor
丹尼尔·朗
崔锡基
保罗·R·法瑟雷
亚当·戈德布卢姆
丹尼尔·马凯斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Shiwan Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiwan Pharmaceutical filed Critical Shiwan Pharmaceutical
Publication of CN101312967A publication Critical patent/CN101312967A/zh
Application granted granted Critical
Publication of CN101312967B publication Critical patent/CN101312967B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800433139A 2005-11-22 2006-11-21 作为5-ht4受体激动剂的氨基甲酸酯化合物 Expired - Fee Related CN101312967B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73870205P 2005-11-22 2005-11-22
US60/738,702 2005-11-22
PCT/US2006/045099 WO2007062058A2 (en) 2005-11-22 2006-11-21 Carbamate compounds as 5-ht4 receptor agonists

Publications (2)

Publication Number Publication Date
CN101312967A CN101312967A (zh) 2008-11-26
CN101312967B true CN101312967B (zh) 2011-08-24

Family

ID=38067868

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800433139A Expired - Fee Related CN101312967B (zh) 2005-11-22 2006-11-21 作为5-ht4受体激动剂的氨基甲酸酯化合物

Country Status (20)

Country Link
US (2) US7329752B2 (https=)
EP (1) EP1960396B1 (https=)
JP (1) JP2009516745A (https=)
KR (1) KR20080072727A (https=)
CN (1) CN101312967B (https=)
AR (1) AR057627A1 (https=)
AT (1) ATE448224T1 (https=)
AU (1) AU2006318507A1 (https=)
BR (1) BRPI0618835A2 (https=)
CA (1) CA2630222A1 (https=)
DE (1) DE602006010432D1 (https=)
EA (1) EA014819B1 (https=)
ES (1) ES2336952T3 (https=)
MY (1) MY143574A (https=)
NO (1) NO20082597L (https=)
NZ (1) NZ567653A (https=)
PE (1) PE20070954A1 (https=)
TW (1) TW200804366A (https=)
WO (1) WO2007062058A2 (https=)
ZA (1) ZA200804010B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163701A (zh) * 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
CN101384588B (zh) * 2006-02-16 2011-08-31 施万制药 制备5-ht4受体激动剂化合物的中间体的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710662A1 (en) * 1994-05-18 1996-05-08 Taisho Pharmaceutical Co. Ltd Quinolinecarboxylic acid derivative
EP0908459A1 (en) * 1997-10-07 1999-04-14 Eli Lilly And Company 5-HT4 Agonists and antagonists
WO2005080389A1 (en) * 2004-02-18 2005-09-01 Theravance, Inc. Indazole-carboxamide compounds as 5-ht4 receptor agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
IT1298271B1 (it) 1998-02-18 1999-12-20 Boehringer Ingelheim Italia Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico
EP1173168A2 (en) 1999-04-28 2002-01-23 Respiratorius AB Compound for use as a medicament for treatment of disorders involving bronchocontraction
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
JP4181847B2 (ja) * 2002-10-25 2008-11-19 エルピーダメモリ株式会社 タイミング調整回路、半導体装置及びタイミング調整方法
KR100738784B1 (ko) 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
WO2006052889A2 (en) * 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
US7399862B2 (en) 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
CA2588037A1 (en) 2004-12-22 2006-06-29 Theravance, Inc. Indazole-carboxamide compounds
CN101163701A (zh) * 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
US7351304B2 (en) * 2005-05-24 2008-04-01 General Electric Company Method and apparatus for reducing surface defects
EP1902053B1 (en) 2005-06-07 2011-01-12 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710662A1 (en) * 1994-05-18 1996-05-08 Taisho Pharmaceutical Co. Ltd Quinolinecarboxylic acid derivative
EP0908459A1 (en) * 1997-10-07 1999-04-14 Eli Lilly And Company 5-HT4 Agonists and antagonists
WO2005080389A1 (en) * 2004-02-18 2005-09-01 Theravance, Inc. Indazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
CA2630222A1 (en) 2007-05-31
US7851467B2 (en) 2010-12-14
EP1960396B1 (en) 2009-11-11
US20080090811A1 (en) 2008-04-17
ZA200804010B (en) 2009-02-25
EA014819B1 (ru) 2011-02-28
EA200801402A1 (ru) 2008-10-30
NZ567653A (en) 2011-06-30
CN101312967A (zh) 2008-11-26
MY143574A (en) 2011-05-31
DE602006010432D1 (de) 2009-12-24
WO2007062058A3 (en) 2007-09-07
PE20070954A1 (es) 2007-09-10
AU2006318507A1 (en) 2007-05-31
US20070117796A1 (en) 2007-05-24
EP1960396A2 (en) 2008-08-27
ATE448224T1 (de) 2009-11-15
NO20082597L (no) 2008-06-10
ES2336952T3 (es) 2010-04-19
JP2009516745A (ja) 2009-04-23
AR057627A1 (es) 2007-12-05
US7329752B2 (en) 2008-02-12
BRPI0618835A2 (pt) 2011-09-13
WO2007062058A2 (en) 2007-05-31
TW200804366A (en) 2008-01-16
KR20080072727A (ko) 2008-08-06

Similar Documents

Publication Publication Date Title
US7674908B2 (en) Indazole-carboxamide compounds as 5-HT4 receptor agonists
JP5159317B2 (ja) インダゾール−カルボキサミド化合物
AU2005233560B2 (en) Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7498442B2 (en) Quinolinone-carboxamide compounds
JP5086091B2 (ja) ５−ｈｔ４受容体アゴニスト化合物
EP1902053B1 (en) Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
JP5042043B2 (ja) ５−ｈｔ４レセプターアゴニストであるキノリン化合物
CN101312967B (zh) 作为5-ht4受体激动剂的氨基甲酸酯化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SCHWAN BIOPHARMA RESEARCH + DEVELOPMENT IP CO., LT

Free format text: FORMER OWNER: SCHWAN PHARMACY

Effective date: 20140828

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140828

Address after: California, USA

Patentee after: THERAVANCE BIOPHARMA R&D IP, LLC

Address before: California, USA

Patentee before: Shi Wanzhiyao

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110824

Termination date: 20211121

CF01 Termination of patent right due to non-payment of annual fee